Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma

Toxicology and Applied Pharmacology

Volumn 268, Issue 3, 2013, Pages 318-330

  Puntel, Mariana ^a,b,e   Ghulam Muhammad, A K M ^b   Farrokhi, Catherine ^b,f   VanderVeen, Nathan ^a   Paran, Christopher ^a   Appelhans, Ashley ^a   Kroeger, Kurt M ^b   Salem, Alireza ^b   Lacayo, Liliana ^b   Pechnick, Robert N ^b,c,g   Kelson, Kyle R ^b   Kaur, Sukhpreet ^b   Kennedy, Sean ^b   Palmer, Donna ^d   Ng, Philip ^d   Liu, Chunyan ^b   Krasinkiewicz, Johnny ^a   Lowenstein, Pedro R ^a,b,c   Castro, Maria G ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^f SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^g WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Bicistronic HC Ad; Biodistribution; Efficacy; Glioblastoma; Neuropathology

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DOXYCYCLINE; ENZYME ANTIBODY; FLT3 LIGAND; NEUTRALIZING ANTIBODY; NITROGEN; THYMIDINE KINASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR CHANGE; BILIRUBIN BLOOD LEVEL; CANCER GENE THERAPY; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE COUNT; GLIOBLASTOMA; LEUKOCYTE COUNT; MALE; NEUROTOXICITY; NONHUMAN; RAT; SURVIVAL TIME; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CYTOTOXINS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; IMMUNIZATION; MALE; RATS; RATS, INBRED LEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADENOVIRIDAE; HERPES; RATTUS;

EID: 84875634078     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.02.001     Document Type: Article

References (78)

1. Aguilar L.K., Guzik B.W., Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J. Cell. Biochem. 2011, 112:1969-1977.
2. Ali S., Curtin J.F., Zirger J.M., Xiong W., King G.D., Barcia C., Liu C., Puntel M., Goverdhana S., Lowenstein P.R., Castro M.G. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther. 2004, 10:1071-1084.
3. Ali S., King G.D., Curtin J.F., Candolfi M., Xiong W., Liu C., Puntel M., Cheng Q., Prieto J., Ribas A., Kupiec-Weglinski J., van Rooijen N., Lassmann H., Lowenstein P.R., Castro M.G. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005, 65:7194-7204.
4. Assi H., Candolfi M., Baker G., Mineharu Y., Lowenstein P.R., Castro M.G. Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci. Lett. 2012, 527:71-77.
5. Aurisicchio L., Delmastro P., Salucci V., Paz O.G., Rovere P., Ciliberto G., La Monica N., Palombo F. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J. Virol. 2000, 74:4816-4823.
6. Bangari D.S., Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 2006, 6:215-226.
7. Barcia C., Jimenez-Dalmaroni M., Kroeger K.M., Puntel M., Rapaport A.J., Larocque D., King G.D., Johnson S.A., Liu C., Xiong W., Candolfi M., Mondkar S., Ng P., Palmer D., Castro M.G., Lowenstein P.R. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol. Ther. 2007, 15:2154-2163.
8. Belalcazar L.M., Merched A., Carr B., Oka K., Chen K.H., Pastore L., Beaudet A., Chan L. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003, 107:2726-2732.
9. Beringer P.M., Owens H., Nguyen A., Benitez D., Rao A., D'Argenio D.Z. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob. Agents Chemother. 2012, 56:70-74.
10. Buckner J.C. Central Nervous System Tumors (Discussion)-Central Nervous System Tumors Track ASCO Annual Meeting 2009, (pp.).
11. Candolfi M., Curtin J.F., Nichols W.S., Muhammad A.G., King G.D., Pluhar G.E., McNiel E.A., Ohlfest J.R., Freese A.B., Moore P.F., Lerner J., Lowenstein P.R., Castro M.G. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol. 2007, 85:133-148.
12. Candolfi M., Kroeger K.M., Muhammad A.K., Yagiz K., Farrokhi C., Pechnick R.N., Lowenstein P.R., Castro M.G. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr. Gene Ther. 2009, 9:409-421.
13. Candolfi M., Yagiz K., Foulad D., Alzadeh G.E., Tesarfreund M., Muhammad A.K., Puntel M., Kroeger K.M., Liu C., Lee S., Curtin J.F., King G.D., Lerner J., Sato K., Mineharu Y., Xiong W., Lowenstein P.R., Castro M.G. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin. Cancer Res. 2009, 15:4401-4414.
14. Candolfi M., Curtin J.F., Yagiz K., Assi H., Wibowo M.K., Alzadeh G.E., Foulad D., Muhammad A.K., Salehi S., Keech N., Puntel M., Liu C., Sanderson N.R., Kroeger K.M., Dunn R., Martins G., Lowenstein P.R., Castro M.G. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 2011, 13:947-960.
15. Candolfi M., King G.D., Yagiz K., Curtin J.F., Mineharu Y., Muhammad A.K., Foulad D., Kroeger K.M., Barnett N., Josien R., Lowenstein P.R., Castro M.G. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 2012, 14:757-770.
16. Castro M.G., Candolfi M., Kroeger K., King G.D., Curtin J.F., Yagiz K., Mineharu Y., Assi H., Wibowo M., Ghulam Muhammad A.K., Foulad D., Puntel M., Lowenstein P.R. Gene therapy and targeted toxins for glioma. Curr. Gene Ther. 2011, 11:155-180.
17. Chiocca E.A., Aguilar L.K., Bell S.D., Kaur B., Hardcastle J., Cavaliere R., McGregor J., Lo S., Ray-Chaudhuri A., Chakravarti A., Grecula J., Newton H., Harris K.S., Grossman R.G., Trask T.W., Baskin D.S., Monterroso C., Manzanera A.G., Aguilar-Cordova E., New P.Z. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J. Clin. Oncol. 2011, 29:3611-3619.
18. Curtin J.F., King G.D., Candolfi M., Greeno R.B., Kroeger K.M., Lowenstein P.R., Castro M.G. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr. Top. Med. Chem. 2005, 5:1151-1170.
19. Curtin J.F., King G.D., Barcia C., Liu C., Hubert F.X., Guillonneau C., Josien R., Anegon I., Lowenstein P.R., Castro M.G. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J. Immunol. 2006, 176:3566-3577.
20. Curtin J.F., Candolfi M., Fakhouri T.M., Liu C., Alden A., Edwards M., Lowenstein P.R., Castro M.G. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008, 3:e1983.
21. Curtin J.F., Candolfi M., Puntel M., Xiong W., Muhammad A.K., Kroeger K., Mondkar S., Liu C., Bondale N., Lowenstein P.R., Castro M.G. Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. Methods Mol. Biol. 2008, 434:239-266.
22. Curtin J.F., Candolfi M., Xiong W., Lowenstein P.R., Castro M.G. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol. Cancer Ther. 2008, 7:439-448.
23. Curtin J.F., Liu N., Candolfi M., Xiong W., Assi H., Yagiz K., Edwards M.R., Michelsen K.S., Kroeger K.M., Liu C., Muhammad A.K., Clark M.C., Arditi M., Comin-Anduix B., Ribas A., Lowenstein P.R., Castro M.G. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009, 6:e10.
24. DuPage M., Cheung A.F., Mazumdar C., Winslow M.M., Bronson R., Schmidt L.M., Crowley D., Chen J., Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19:72-85.
25. Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med. 2007, 9:833-842.
26. Ehrhardt A., Xu H., Dillow A.M., Bellinger D.A., Nichols T.C., Kay M.A. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 2003, 102:2403-2411.
27. FDA Guidance for industry. Gene therapy clinical trials. Observing Subjects for Delayed Adverse Events 2006, 25.
28. Fiedler M., Rodicker F., Salucci V., Lu M., Aurisicchio L., Dahmen U., Jun L., Dirsch O., Putzer B.M., Palombo F., Roggendorf M. Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J. Virol. 2004, 78:10111-10121.
29. Fukazawa T., Matsuoka J., Yamatsuji T., Maeda Y., Durbin M.L., Naomoto Y. Adenovirus-mediated cancer gene therapy and virotherapy (review). Int. J. Mol. Med. 2010, 25:3-10.
30. Ghulam Muhammad A.K., Candolfi M., King G.D., Yagiz K., Foulad D., Mineharu Y., Kroeger K.M., Treuer K.A., Nichols W.S., Sanderson N.S., Yang J., Khayznikov M., Van Rooijen N., Lowenstein P.R., Castro M.G. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin. Cancer Res. 2009, 15:6113-6127.
31. Gonin P., Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther. 2004, 11(Suppl. 1):S98-S108.
32. Goverdhana S., Puntel M., Xiong W., Zirger J.M., Barcia C., Curtin J.F., Soffer E.B., Mondkar S., King G.D., Hu J., Sciascia S.A., Candolfi M., Greengold D.S., Lowenstein P.R., Castro M.G. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 2005, 12:189-211.
33. Grossman S.A., Ye X., Piantadosi S., Desideri S., Nabors L.B., Rosenfeld M., Fisher J., N.C.Consortium Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. ASCO Annual Meeting 2009, (pp.).
34. Harrington K.J., Hingorani M., Tanay M.A., Hickey J., Bhide S.A., Clarke P.M., Renouf L.C., Thway K., Sibtain A., McNeish I.A., Newbold K.L., Goldsweig H., Coffin R., Nutting C.M. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 2010, 16:4005-4015.
35. Harvey B.G., Hackett N.R., El-Sawy T., Rosengart T.K., Hirschowitz E.A., Lieberman M.D., Lesser M.L., Crystal R.G. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 1999, 73:6729-6742.
36. Kim I.A., Yang Y.J., Yoon S.C., Choi I.B., Kay C.S., Kwon H.C., Kim C.M., Joe Y.A., Kang J.K., Hong Y.K. Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas. Int. J. Oncol. 2001, 19:1041-1047.
37. King G.D., Kroeger K.M., Bresee C.J., Candolfi M., Liu C., Manalo C.M., Muhammad A.K., Pechnick R.N., Lowenstein P.R., Castro M.G. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol. Ther. 2008, 16:682-690.
38. King G.D., Muhammad A.G., Xiong W., Kroeger K.M., Puntel M., Larocque D., Palmer D., Ng P., Lowenstein P.R., Castro M.G. High-capacity adenoviral vector-mediated anti-glioma gene therapy in the presence of systemic anti-adenovirus immunity. J. Virol. 2008, 82:4680-4684.
39. King G.D., Muhammad A.K., Curtin J.F., Barcia C., Puntel M., Liu C., Honig S.B., Candolfi M., Mondkar S., Lowenstein P.R., Castro M.G. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol. 2008, 10:19-31.
40. King G.D., Muhammad A.K., Larocque D., Kelson K.R., Xiong W., Liu C., Sanderson N.S., Kroeger K.M., Castro M.G., Lowenstein P.R. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol. Ther. 2011, 19:1793-1801.
41. Kojima H., Fujimiya M., Matsumura K., Younan P., Imaeda H., Maeda M., Chan L. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat. Med. 2003, 9:596-603.
42. Kroeger K.M., Muhammad A.K., Baker G.J., Assi H., Wibowo M.K., Xiong W., Yagiz K., Candolfi M., Lowenstein P.R., Castro M.G. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov. Med. 2010, 10:293-304.
43. Lamartina S., Cimino M., Roscilli G., Dammassa E., Lazzaro D., Rota R., Ciliberto G., Toniatti C. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J. Gene Med. 2007, 9:862-874.
44. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
45. Maatta A.M., Samaranayake H., Pikkarainen J., Wirth T., Yla-Herttuala S. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr. Gene Ther. 2009, 9:356-367.
46. Mian A., McCormack W.M., Mane V., Kleppe S., Ng P., Finegold M., O'Brien W.E., Rodgers J.R., Beaudet A.L., Lee B. Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol. Ther. 2004, 10:492-499.
47. Micromedex, Retrieved December 2012. Truven Health Analytics.
48. Mineharu Y., Muhammad A.K., Yagiz K., Candolfi M., Kroeger K.M., Xiong W., Puntel M., Liu C., Levy E., Lugo C., Kocharian A., Allison J.P., Curran M.A., Lowenstein P.R., Castro M.G. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-kappaB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics 2012, 9:827-843.
49. Morsy M.A., Gu M., Motzel S., Zhao J., Lin J., Su Q., Allen H., Franlin L., Parks R.J., Graham F.L., Kochanek S., Bett A.J., Caskey C.T. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7866-7871.
50. Muhammad A.K., Puntel M., Candolfi M., Salem A., Yagiz K., Farrokhi C., Kroeger K.M., Xiong W., Curtin J.F., Liu C., Lawrence K., Bondale N.S., Lerner J., Baker G.J., Foulad D., Pechnick R.N., Palmer D., Ng P., Lowenstein P.R., Castro M.G. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin. Pharmacol. Ther. 2010, 88:204-213.
51. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., Robbins P.D., Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 2004, 11:351-357.
52. Oka K., Pastore L., Kim I.H., Merched A., Nomura S., Lee H.J., Merched-Sauvage M., Arden-Riley C., Lee B., Finegold M., Beaudet A., Chan L. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001, 103:1274-1281.
53. Palmer D.J., Ng P. Methods for the production of helper-dependent adenoviral vectors. Methods Mol. Biol. 2008, 433:33-53.
54. Palmer D.J., Ng P. Rescue, amplification, and large-scale production of helper-dependent adenoviral vectors. Cold Spring Harb. Protoc. 2011, 2011:857-866.
55. Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A., Graham F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13565-13570.
56. Pastore L., Belalcazar L.M., Oka K., Cela R., Lee B., Chan L., Beaudet A.L. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 2004, 327:153-160.
57. Pluhar G.E., Grogan P.T., Seiler C., Goulart M., Santacruz K.S., Carlson C., Chen W., Olin M.R., Lowenstein P.R., Castro M.G., Haines S.J., Ohlfest J.R. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010, 28:3371-3378.
58. Puntel M., Curtin J.F., Zirger J.M., Muhammad A.K., Xiong W., Liu C., Hu J., Kroeger K.M., Czer P., Sciascia S., Mondkar S., Lowenstein P.R., Castro M.G. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum. Gene Ther. 2006, 17:531-544.
59. Puntel, M., Kroeger, K.M., Sanderson, N.S., Thomas, C.E., Castro, M.G., Lowenstein, P.R., 2010a. Gene transfer into rat brain using adenoviral vectors. Current protocols in neuroscience/editorial board, Jacqueline N. Crawley [et al.] Chapter 4, Unit 4 2.
60. Puntel M., Muhammad A.K., Candolfi M., Salem A., Yagiz K., Farrokhi C., Kroeger K.M., Xiong W., Curtin J.F., Liu C., Bondale N.S., Lerner J., Pechnick R.N., Palmer D., Ng P., Lowenstein P.R., Castro M.G. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J. Virol. 2010, 84:6007-6017.
61. Reddy P.S., Sakhuja K., Ganesh S., Yang L., Kayda D., Brann T., Pattison S., Golightly D., Idamakanti N., Pinkstaff A., Kaloss M., Barjot C., Chamberlain J.S., Kaleko M., Connelly S. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol. Ther. 2002, 5:63-73.
62. Schillinger K.J., Tsai S.Y., Taffet G.E., Reddy A.K., Marian A.J., Entman M.L., Oka K., Chan L., O'Malley B.W. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13789-13794.
63. Schmitz H., Wigand R., Heinrich W. Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol. 1983, 117:455-466.
64. Senzer N.N., Kaufman H.L., Amatruda T., Nemunaitis M., Reid T., Daniels G., Gonzalez R., Glaspy J., Whitman E., Harrington K., Goldsweig H., Marshall T., Love C., Coffin R., Nemunaitis J.J. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 2009, 27:5763-5771.
65. Southgate T., Kroeger K.M., Liu C., Lowenstein P.R., Castro M.G. Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci 2008, vol. 45:4.23.1-4.23.43. John Wiley & Sons, Inc., Chichester, New York.
66. Stupp R., Mason W.P., Van Den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
67. Stupp R., Hegi M.E., Van Den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., Cairncross J.G. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006, 11:165-180.
68. Stupp R., Hottinger A.F., van den Bent M.J., Dietrich P.Y., Brandes A.A. Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. Ann. Oncol. 2008, 19(Suppl. 7):vii209-vii216.
69. Teh B.S., Ayala G., Aguilar L., Mai W.Y., Timme T.L., Vlachaki M.T., Miles B., Kadmon D., Wheeler T., Caillouet J., Davis M., Carpenter L.S., Lu H.H., Chiu J.K., Woo S.Y., Thompson T., Aguilar-Cordova E., Butler E.B. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:1520-1529.
70. Terashima T., Oka K., Kritz A.B., Kojima H., Baker A.H., Chan L. DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Invest. 2009, 119:2100-2112.
71. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., Lowenstein P.R. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7482-7487.
72. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., Lowenstein P.R. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther. 2001, 12:839-846.
73. Voisin E.M., Ruthsatz M., Collins J.M., Hoyle P.C. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul. Toxicol. Pharmacol. 1990, 12:107-116.
74. Wei J., DeAngulo G., Sun W., Hussain S.F., Vasquez H., Jordan J., Weinberg J., Wolff J., Koshkina N., Heimberger A.B. Topotecan enhances immune clearance of gliomas. Cancer Immunol. Immunother. 2009, 58:259-270.
75. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359:492-507.
76. Xiong W., Goverdhana S., Sciascia S.A., Candolfi M., Zirger J.M., Barcia C., Curtin J.F., King G.D., Jaita G., Liu C., Kroeger K., Agadjanian H., Medina-Kauwe L., Palmer D., Ng P., Lowenstein P.R., Castro M.G. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol. 2006, 80:27-37.
77. Xiong W., Candolfi M., Kroeger K.M., Puntel M., Mondkar S., Larocque D., Liu C., Curtin J.F., Palmer D., Ng P., Lowenstein P.R., Castro M.G. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol. Ther. 2008, 16:343-351.
78. Yang J., Sanderson N.S., Wawrowsky K., Puntel M., Castro M.G., Lowenstein P.R. Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4716-4721.